FeesSafety
Pluang+

Enlight Renewable Energy reports 40% revenue growth in Q3 2026, raises 2026 guidance amid strong project expansion.

Company Fundamentals
03 Nov 2026, 13:00 WIB
GlobeNewsWire
View Source
Bullish
Enlight Renewable Energy reports 40% revenue growth in Q3 2026, raises 2026 guidance amid strong project expansion.

Enlight Renewable Energy posted a 40% increase in total revenues to $231 million for Q3 2026, driven by new projects, higher electricity prices in Europe, and expanded electricity trading in Israel. Adjusted EBITDA rose 38% to $154 million, with net income up 4% to $34 million despite a one-time $20 million expense from terminating two U.S. PPAs. The company expanded its portfolio to 46.2 FGW, emphasizing energy storage growth and advancing major U.S. projects like the CO-Bar complex. Enlight raised its 2026 revenue guidance to $810-$830 million and adjusted EBITDA guidance to $575-$590 million, reflecting strong operational performance and market conditions.

Enlight Renewable Energy's Q3 2026 results provide context for energy sector performance. As of Nov 03, 2026 15:41 WIB, among 79 priced US energy stocks on Pluang, 37 rose and 36 fell. Notable movers include YPF at USD 44.15 with a 6.06% decline, Solaris Energy Infrastructure Inc. (SEI) at USD 66.46 down 6.00% with 100% sell order activity, and Permian Resources Corporation (PR) at USD 24.56 down 5.61%.

More News

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...

Company Fundamentals
Bullish
1 hour ago
Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...

Market News
Bullish
1 hour ago
Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...

Market News
Bullish
1 hour ago
Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...

Company Fundamentals
Neutral
2 hours ago
Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones Inc. announced a conference call for November 4, 2026, at 10:00 AM EST to discuss its third quarter 2026 financial results. The call is open to investors, analysts, and interested parties and will be webcast live with a recording availab...

Company Fundamentals
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App